Divis Laboratories has received an Import Alert 66-40 from US Food and Drug Administration (USFDA) for its products manufactured at the company’s Unit-II located at Visakhapatnam, Andhra Pradesh on March 20, 2017.
The agency has exempted the following products from the Import Alert – Levetiracetam, Gabapentin, Lamotrigine, Capecitabine, Naproxen sodium, Raltegravir potassium, Atovaquone, Chloropurine, BOC core succinate, 2, 4-wing active ester. The company along with third party consultants is currently working to address the concerns of the USFDA and is making all efforts to fully meet the compliance requirements.
Divis Laboratories focussed on developing new processes for the production of Active Pharma Ingredients (APIs) & Intermediates. The company in a matter of short time expanded its breadth of operations to provide complete turnkey solutions to the domestic Indian pharmaceutical industry.
